Signalrx Pharmaceuticals, Inc.

San Diego, CA 92130

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $1.83MM
First Award Date 04/08/15
Most Recent Award Date 07/11/17

Key Personnel

Last Name Name Awards Contact
DURDEN DONALD DURDEN 3

3 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 07/11/17 - 06/30/18

There is an unmet need to inhibit the key cancer promoting transcription factor MYC (both c-MYC and MYCN) that act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growth. To date, small molecule inhibitors of MYC have remained elusive. In our Phase I STTR (CA192656), we d...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 09/22/16 - 09/19/17

PARP inhibitors (PARPi) are particularly efficacious in tumors deficient in the BRCA1/2 tumor suppressor genes but of limited activity in BRCA competent tumors. There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA1/2 wild type cancers and to increase chemo- radiosensitivity in these mal...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 04/08/15 - 03/31/16

DESCRIPTION (provided by applicant): There is an unmet need to inhibit the key cancer promoting transcription factor MYC. MYC (both cMYC and MYCN) acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation. To date, small molecule inhibitors of MYC have been ...